These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8983935)
21. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. Karjalainen MJ; Neuvonen PJ; Backman JT Eur J Clin Pharmacol; 2007 Sep; 63(9):829-36. PubMed ID: 17618427 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man. Pentikäinen PJ; Tokola O; Alhava E; Penttilä A Eur J Clin Pharmacol; 1984; 27(3):349-54. PubMed ID: 6334608 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of tolfenamic acid after different administration routes in geese (Anser cygnoides). Turk E; Tekeli IO; Durna Corum D; Corum O; Sakin F; Uney K J Vet Pharmacol Ther; 2021 May; 44(3):381-387. PubMed ID: 33598927 [TBL] [Abstract][Full Text] [Related]
24. High-performance liquid chromatographic (HPLC) determination of lobenzarit in plasma and its application to a bioavailability study in beagle dogs. Schwende FJ; Turner SW Pharm Res; 1991 Apr; 8(4):523-6. PubMed ID: 1871051 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver. Stenderup J; Eriksen J; Pedersen SB; Christiansen LV Eur J Clin Pharmacol; 1985; 28(5):573-9. PubMed ID: 3876221 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of tolfenamic acid in green sea turtles (Chelonia mydas) after intravenous and intramuscular administration. Raweewan N; Chomcheun T; Laovechprasit W; Jongkolpath O; Klangkaew N; Phaochoosak N; Giorgi M; Poapolathep A; Poapolathep S J Vet Pharmacol Ther; 2020 Nov; 43(6):527-532. PubMed ID: 32524632 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and bioavailability of percutaneous ibuprofen. Kleinbloesem CH; Ouwerkerk M; Spitznagel W; Wilkinson FE; Kaiser RR Arzneimittelforschung; 1995 Oct; 45(10):1117-21. PubMed ID: 8595072 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of tiaprofenic acid in infants after a single oral dose. Pariente-Khayat A; Dubois MC; Vauzelle-Kervroëdan F; Rey E; D'Athis P; D'Yvoire MB; Saint-Maurice C; Olive G; Pons G Int J Clin Pharmacol Ther; 1996 Aug; 34(8):342-4. PubMed ID: 8864796 [TBL] [Abstract][Full Text] [Related]
29. Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep. Cetin G; Durna Corum D; Corum O; Atik O; Coskun D; Uney K J Vet Pharmacol Ther; 2021 Nov; 44(6):945-951. PubMed ID: 34312894 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of tiaprofenic acid in children after a single oral dose. Bertin L; Rey E; Pons G; Mathiot JL; Richard MO; Chrétien P; Saint-Maurice C; Moran C; Ginisty D; Olive G Eur J Clin Pharmacol; 1991; 41(3):251-3. PubMed ID: 1748142 [TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. Manvelian G; Daniels S; Gibofsky A Postgrad Med; 2012 Jan; 124(1):117-23. PubMed ID: 22314121 [TBL] [Abstract][Full Text] [Related]
33. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Tokola RA; Neuvonen PJ Br J Clin Pharmacol; 1984 Jan; 17(1):67-75. PubMed ID: 6691890 [TBL] [Abstract][Full Text] [Related]
34. The influence of fever on the pharmacokinetics of pranoprofen in elderly subjects. Fujimura A; Kajiyama H; Ebihara A J Clin Pharmacol; 1989 Jun; 29(6):500-3. PubMed ID: 2787808 [TBL] [Abstract][Full Text] [Related]
35. Role of the Abcg2 transporter in plasma levels and tissue accumulation of the anti-inflammatory tolfenamic acid in mice. Blanco-Paniagua E; García-Lino AM; García-Mateos D; Álvarez AI; Merino G Chem Biol Interact; 2021 Aug; 345():109537. PubMed ID: 34062171 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. Choi Y; Han H; Shin D; Lim KS; Yu KS Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511 [TBL] [Abstract][Full Text] [Related]
37. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of cetirizine in 2- to 6-year-old children. Pariente-Khayat A; Rey E; Dubois MC; Vauzelle-Kervroedan F; Pons G; D'athis P; Murat II; Pinelli ME; Saint-Maurice C; Olive G Int J Clin Pharmacol Ther; 1995 Jun; 33(6):340-4. PubMed ID: 7582385 [TBL] [Abstract][Full Text] [Related]
39. Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. Valles J; Artigas R; Bertolotti M; Crea A; Muller F; Paredes I; Capriati A Methods Find Exp Clin Pharmacol; 2006 Jun; 28 Suppl A():29-36. PubMed ID: 16801990 [TBL] [Abstract][Full Text] [Related]
40. A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. Maya MT; Pais JP; Ruas Da Silva J; Morais JA Eur J Drug Metab Pharmacokinet; 1995; 20(4):275-9. PubMed ID: 8983932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]